Pfizer collaborates on drugs for Russian market

Friday, July 1, 2011 10:08 AM

Pfizer will work with a Russian venture capital company to research and market new drugs in Russia and surrounding countries, according to the Associated Press.

Pfizer said it will work with ChemRar High Tech Center to explore research, development and marketing of drugs and vaccines to treat heart and metabolic illnesses, infectious diseases and cancer. It said those conditions are a high priority for the Russian Federation health care system.

Pfizer and ChemRar did not disclose any financial terms. The partnership plans to seek technology transfer and licensing deals for drugs in Pfizer's pipeline of developing drugs.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs